Your search relates to more than one category
SeekingAlpha.com (Free subscription) | 11/26/2009
Zacks.com submits: Boston Scientific Corp. ( BSX ) recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval to market its WallFlex Fully Covered Esophageal Stent in the U.S. and Europe. The new product is used for the treatment of malignant esophageal strictures (obstructions) caused by tumors in patients with resectable or non-resectable...
MassDevice - Medical device news, information and jobs... (Free subscription) | 11/23/2009
Boston Scientific Corp. plans to shutter a plant in Doral, Fla., laying off 1,400 workers as it moves the operation to Costa Rica. Boston Scientific Corp. (NYSE:BSX) plans to shutter a plant in Doral, Fla., laying off 1,400 workers, The Miami Herald reported. The Natick, Mass.-based medical devices giant is relocating the Doral operation to a vacant facility in Costa Rica...
Drug and Device Law (Free subscription) | 11/23/2009
Here's today's question: What do we think of McQuiston v. Boston Scientific Corp., No. 5:07-cv-01723-TS-MLH, slip op. (W.D. La. Nov. 19, 2009) ( link here )? Here's today's answer: We love it! But not for the reasons you'd think. Here's the deal: On September 1, 2006, Dr. Thomas Brown performed an angioplasty and stent procedure on James McQuiston. Boston Scientific manufactured...
San Fransisco Chronicle (Free subscription) | 11/23/2009
... attention to sales of heart rhythm devices, following weaker-than-expected sales by competitors Boston Scientific Corp. and St. Jude Medical. St. Jude saw sales decline, while Boston Scientific seemed to resort to price cuts to keep sales moving, according to Lazard Capital Markets analyst Sean Lavin."We find it unlikely that Medtronic could be completely unaffected," said...
Seattle Post-Intelligencer (Free subscription) | 11/23/2009
... attention to sales of heart rhythm devices, following weaker-than-expected sales by competitors Boston Scientific Corp. and St. Jude Medical. St. Jude saw sales decline, while Boston Scientific seemed to resort to price cuts to keep sales moving, according to Lazard Capital Markets analyst Sean Lavin."We find it unlikely that Medtronic could be completely unaffected," said...
